Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations

Poly ADP-ribose polymerase inhibitor (PARPi) has become an important maintenance therapy for ovarian cancer after surgery and cytotoxic chemotherapy, which has changed the disease management model of ovarian cancer, greatly decreased the risk of recurrence, and made the prognosis of ovarian cancer b...

Full description

Saved in:
Bibliographic Details
Main Authors: Qin Xu, Zhengyu Li
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
Online Access:https://doaj.org/article/adeb1491c1634704849a192d2caa2986
Tags: Add Tag
No Tags, Be the first to tag this record!